DefinitionThis section has been translated automatically.
Cytostatic, antimetabolite, purine antagonist.
Pharmacodynamics (Effect)This section has been translated automatically.
Irreversible catalysis of the deamination from adenosine to inosine and from deoxyadenosine to deoxyinosine. Disruption of DNA synthesis, induction of apoptosis.
You might also be interested in
IndicationThis section has been translated automatically.
Hair cell leukemia, B-cell type CLL, prolymphocytic leukemia, cutaneous T-cell lymphomas.
Dosage and method of useThis section has been translated automatically.
4 mg/m2 KO/day i.v. as a bolus every 2 weeks
Notice!
Before administration intravenous fluid substitution of 500-1000 ml!Undesirable effectsThis section has been translated automatically.
Myelosuppression, nausea, allergic reactions, fever, fatigue, headaches, liver and kidney dysfunction.
InteractionsThis section has been translated automatically.
Myelotoxic substances.
ContraindicationThis section has been translated automatically.
Pregnancy, lactation, children < 16 years.
PreparationsThis section has been translated automatically.
Nipent
Prof. Dr. med. Peter Altmeyer